At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Triple-blind, Placebo-controlled, Parallel Clinical Trial to Investigate the Safety and Efficacy of NeuroQ on Cognitive Function in Healthy Adults with Self-reported Memory Problems.
In Brief
A Phase 2 clinical trial evaluating NeuroQ and Placebo for Healthy and Self-reported Memory Problems. Completed, enrolled 40 participants across 1 site.
Detailed Summary
The objective of this study is to investigate the safety and efficacy of NeuroQ on cognitive function in a North American population of healthy adults with self-reported memory problems compared to placebo. The difference in change in cognitive function as assessed by the CNS Vital Signs (CNS VS) Neurocognitive Index (NCI) score between NeuroQ and placebo will be measured from baseline at Day 60. Additionally, the safety and tolerability of NeuroQ, as compared to placebo, will be measured by the occurrence of and/or changes in treatment-emergent adverse events (AEs). Participants will take two capsules containing NeuroQ or placebo once a day for 60 days, have 4 in-person clinic visits, and keep a diary of their symptoms and number of missed doses.
Study Details
Timeline
Interventions
Two (2) capsules of NeuroQ taken once a day for 60 days.
Two (2) capsules of placebo taken once a day for 60 days.